Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In…
| Price | $1,154.66 |
|---|---|
| Market cap | $1.09T |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Exchange | NYSE |
| 52-week range | 712.05-1292.65 |
| Dividend (TTM) | $6.69 per share |
| Beta | 0.5 |
Explore LLY's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.